Caribou Biosciences, Inc. cotiza a 0.47 USD y tiene una capitalización bursátil de $50M. En los últimos 12 meses ha facturado $10M con un margen de flujo de caja libre del -1006.8%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell th…
| Periodo | 2026-11 | 2026-08 | 2026-08 | 2026-05 |
|---|---|---|---|---|
| Real | — | $-0.24 | — | $-0.26 |
| Estimado | $-0.26 | $-0.31 | $-0.31 | $-0.31 |
| Sorpresa | — | +22.6% | — | +16.1% |
| Métrica | CRBU | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -1329.4% | -38.6% | -1290.8% |
| Net Margin | -1327.4% | -33.6% | -1293.8% |
| FCF Margin | -1006.8% | -13.9% | -993.0% |
| ROE | -121.2% | -40.4% | -80.8% |
| ROA | -84.5% | -32.0% | -52.5% |
| Current Ratio | 5.71 | 2.84 | +2.87 |
| Debt / Equity | — | 0.28 | — |